Company intelligence / Profile preview

Calyxha Biotechnologies

Ownership: Private
Development stage: Preclinical

Overview

Developing CAL-4 as an inhaled drug for asthma, predicted to bring benefits of steroid treatment without side effects. Currently in pre-clinical stage with clinical trials planned for 2025.

Therapeutic areas: PulmonologyNeurologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CAL-4

Pre-clinical

Indications: Asthma

Partnerships

Industry partnerships mentioned but specific partners not named

Beyond the preview

Go deeper on Calyxha Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calyxha Biotechnologies.

Explore the full profile